Extension of Warrants

RNS Number : 7595J
Barkby Group PLC (The)
24 December 2020
 

The Barkby Group PLC

("Barkby", the "Group" or the "Company")

Extension of Warrants

The Barkby Group PLC, the diversified business group, announces that its Remuneration Committee have agreed to extend the expiry date of warrants ("Warrants") over ordinary shares of £0.00860675675675676 each in the capital of the Company ("Ordinary Shares") held by Rupert Fraser, Group Managing Director of the Company.

All other aspects of the Warrants are unchanged and are listed below:

Investor Name

Warrants

Exercise Price

Value

Granted

Initial Expiry

New Expiry

Rupert Fraser

1,452,347

8.6p

£124,901.84

30/12/2015

30/12/2020

30/12/2021

 

Related Party Transaction

The Warrants are held by Rupert Fraser, a Director of the Company. Accordingly, the extension to the expiry date of the Warrants constitutes a related party transaction under Rule 13 of the AIM Rules for Companies. The independent Directors, having consulted with the Company's nominated adviser, finnCap Ltd, consider that the terms of the transaction are fair and reasonable insofar as the Company's shareholders are concerned.

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

 

Enquiries: 

 

The Barkby Group PLC


Charles Dickson, Executive Chairman

Douglas Benzie, Chief Financial Officer






finnCap Ltd (Nomad and Broker)

+44 (0) 20 7220 0500

Carl Holmes/Simon Hicks (corporate finance)

Tim Redfern/Richard Chambers (ECM)






Camarco (Financial PR)

+44 (0) 20 3757 4994

Jennifer Renwick/Jake Thomas

 

Notes to editors

 

The Barkby Group PLC is a diversified group of high growth, high quality businesses run by an entrepreneurial and experienced management team. The existing wholly owned businesses within Barkby include; Commercial Property Development, Barkby Hospitality (comprising Barkby Pubs and Workshop Coffee) and Centurian Automotive.

 

In addition to these businesses, Barkby Life Sciences has invested in VivoPlex, a digital health company aiming to transform Women's Health with precision medicine, and its subsidiary Cambridge Sleep Sciences Ltd has launched, SleepHub™, a device which improves and facilitates natural sleep.

 

Barkby's strategy is to accelerate and maximise opportunities within its existing businesses as well as continue to source and invest in cash generative, growth businesses with the ability to disrupt.



 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1. 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Rupert Fraser

2. 

Reason for the notification

a)

Position/status:

Group Managing Director

b)

Initial notification/Amendment:

Initial Notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

The Barkby Group plc

b)

LEI:

213800X57YXZVILB9E84

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Warrants over Ordinary Shares of £0.00860675675675676

GB00BL6TZZ70

b)

Nature of the transaction:

Extension of warrant expiry date from 30 December 2020 to 30 December 2021

c)

Price(s) and volume(s):

Price(s) pence

Volume(s)

n/a

1,452,347

d)

Aggregated information:

· Aggregated volume:

· Price:

n/a

e)

Date of the transaction:

24 December 2020

f)

Place of the transaction:

Off market transaction

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHPPGCPPUPUPWW
UK 100

Latest directors dealings